Cidoxepin

Cidoxepin (former developmental code name P-4599), also known as cis-doxepin or (Z)-doxepin, is a tricyclic antidepressant which was developed in the 1960s but was never marketed.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Cidoxepin (former developmental code name P-4599), also known as cis-doxepin or (Z)-doxepin, is a tricyclic antidepressant which was developed in the 1960s but was never marketed. It is the cis or (Z) stereoisomer of doxepin, a mixture of (E) and (Z) isomers that is used commercially in a ratio of approximately 17:3 with cidoxepin as a relatively minor constituent.

However, the drug has similar activity to that of doxepin, acting as a serotonin–norepinephrine reuptake inhibitor, H 1 receptor antagonist, and anticholinergic, and notably is thought to have more antidepressant activity than trans-doxepin. The central anticholinergic activity of cidoxepin has been reported to be 3-fold greater than that of the trans isomer in mice.

Cidoxepin has recently been reinvestigated and is now currently under development as an antihistamine by Elorac, Inc. for the treatment of chronic urticaria (hives). As of 2017, it is in phase II clinical trials for this indication.

The drug was also under investigation for the treatment of allergic rhinitis (hay fever), atopic dermatitis (atopic eczema), and contact dermatitis, but development for these indications was discontinued.

See also

Esmirtazapine Nordoxepin

Cidoxepin - AdisInsight

Text derived from https://en.wikipedia.org/w/index.php?oldid=1370743912 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

3 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.